SMW Free Realtime Trade Alerts -- Fast Moving Stocks < $15 -- Join Today for FREE!!

Prosensa Holding NV
(NASDAQ : RNA)

( )
RNA After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
Loading RNA News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
1.62%79.121.1%$779.04m
AMGNAmgen Inc.
0.81%166.791.2%$478.24m
SRPTSarepta Therapeutics, Inc.
0.71%61.4127.0%$477.71m
BIIBBiogen Inc.
2.37%313.031.1%$447.74m
CELGCelgene Corporation
1.69%104.510.9%$402.67m
MDVNMedivation, Inc.
0.05%81.481.9%$381.25m
REGNRegeneron Pharmaceuticals, Inc.
-1.07%402.023.7%$314.38m
CPHDCepheid
-0.08%52.695.5%$220.42m
ALXNAlexion Pharmaceuticals, Inc.
2.07%122.542.2%$181.45m
CLVSClovis Oncology, Inc.
4.07%36.0528.4%$159.66m
ILMNIllumina, Inc.
2.89%181.663.4%$148.67m
VRTXVertex Pharmaceuticals Incorporated
2.60%87.212.3%$139.76m
INCYIncyte Corporation
2.17%94.292.8%$132.54m
TSROTESARO, Inc.
-0.34%100.2417.5%$113.57m
BMRNBioMarin Pharmaceutical Inc.
-0.28%92.524.0%$112.23m

Company Profile

Prosensa Holding NV engages in the development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The company focuses on rare neuromuscular and neurodegenerative disorders, Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. It has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. Prosensa's current clinical portfolio is focused on the treatment of Duchenne Muscular Dystrophy. The company was founded in 2002 and is headquartered in Leiden, the Netherlands.